A community-centered approach to psychedelics.
Discover Mental Health November 27, 2025 DOI: 10.1007/s44192-025-00350-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | Argues that while psilocybin and MDMA show potential for treating PTSD and depression in supportive contexts, their move toward mainstream adoption risks rapid medicalization, corporate monopolization, and repeating past public health failures. |
Abstract
The renewed interest in psychedelics for mental health treatment presents both promise and complexity. Substances like psilocybin and MDMA have shown potential in addressing conditions such as PTSD and depression, particularly when administered in supportive contexts. Yet as these therapies move toward mainstream adoption, concerns arise about rapid medicalization, corporate monopolization, and the possibility of replicating past public health failures.
Citations in the library
Cites 18
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Global Street Food: la cocina de la calle Diseño interior 2009
- Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 2018
- Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial American Journal of Psychiatry December 5, 2017
- Psychedelics reopen the social reward learning critical period Nature June 14, 2023
and 13 more in the library